Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
GlaxoSmithKline PharmaceuticalsNSE:GLAXO +1.77%73 ROC (Joel Greenblatt) % is 487.80% as of Mar. 2026, which is 218% above its 10-year median of 153.41. GuruFocus rates NSE:GLAXO with a GF Score™ of 73/100 and a GF Value™ of ₹2,627.94 (Fairly Valued). The stock has 1 warning sign investors should review. Among 983 Drug Manufacturers companies, GlaxoSmithKline Pharmaceuticals ranks better than 98.37% on this metric.
Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits). He defines ROC (Joel Greenblatt) % as EBIT divided by the total of Property, Plant and Equipment and net working capital. GlaxoSmithKline Pharmaceuticals's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was 487.80%.
The historical rank and industry rank for GlaxoSmithKline Pharmaceuticals's ROC (Joel Greenblatt) % or its related term are showing as below:
NSE:GLAXO'
s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: 28.39 Med: 153.41 Max: 477.3
Current: 475.39
During the past 13 years, GlaxoSmithKline Pharmaceuticals's highest ROC (Joel Greenblatt) % was 477.30%. The lowest was 28.39%. And the median was 153.41%.
NSE:GLAXO's ROC (Joel Greenblatt) % is ranked better than 98.37% of 983
companies
in the Drug Manufacturers industry
Industry Median: 11.46
vs NSE:GLAXO: 475.39
The way Joel Greenblatt defines Return on Capital is a more accurate measure of how efficiently the company generates returns onthe capital actually invested in the business. EBIT is used instead of net income because the tax and interest payment may be affected by factors other than the core business operation. Intangible assets are not included in the calculation because they don't need to be replaced.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NSE:GLAXO vs LLY, JNJ, ABBV: ROC (Joel Greenblatt) % Comparison
For the Drug Manufacturers - General subindustry, GlaxoSmithKline Pharmaceuticals's ROC (Joel Greenblatt) %, along with its competitors' market caps and ROC (Joel Greenblatt) % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
GlaxoSmithKline Pharmaceuticals ROC (Joel Greenblatt) % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, GlaxoSmithKline Pharmaceuticals's ROC (Joel Greenblatt) % distribution charts can be found below:
* The bar in red indicates where GlaxoSmithKline Pharmaceuticals's ROC (Joel Greenblatt) % falls into.
Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits) . He defines Return on Capital as follows:
EBIT stands for Earnings Before Interest and Taxes.
Fixed Assets are also known as non-current assets. They include the Property, Plant and Equipment that the firm needs in its operation.
GuruFocus calculates net working capital as: (Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Deferred Revenue + Other Current Liabilities). We're trying to account for OPERATING assets and liabilities (part of daily business) when calculating working capital. Cash and marketable securities are considered NON-OPERATING assets and are not included in calculation. We will also back out all interest bearing debt, short term debt and the portion of long term debt that is due in the current period from the current liabilities. This debt will be considered when computing cost of capital and it would be inappropriate to count it twice.
Note:
The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a ROC (Joel Greenblatt) % of 487.80% mean?
GlaxoSmithKline Pharmaceuticals (NSE:GLAXO) has a ROC (Joel Greenblatt) % of 487.80% as of Mar. 2026. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on GlaxoSmithKline Pharmaceuticals and its competitors. This is 218% above median its historical median of 153.41. Over the past decade, GlaxoSmithKline Pharmaceuticals' ROC (Joel Greenblatt) % has ranged from 28.39 to 477.30. According to the industry distribution chart, GlaxoSmithKline Pharmaceuticals ranks #16 out of 983 companies in the Drug Manufacturers industry, placing it in the top 1.6%.
Is GlaxoSmithKline Pharmaceuticals' ROC (Joel Greenblatt) % too high?
GlaxoSmithKline Pharmaceuticals' current ROC (Joel Greenblatt) % of 487.80% is 218% above median its 10-year median of 153.41. Over the past 10 years, this metric has ranged from a low of 28.39 to a high of 477.30. The Drug Manufacturers industry median ROC (Joel Greenblatt) % is 11.46. GlaxoSmithKline Pharmaceuticals' value of 487.80% is 4156.5% above this industry median. Based on the distribution chart, GlaxoSmithKline Pharmaceuticals ranks #16 out of 983 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, GlaxoSmithKline Pharmaceuticals has a GF Score™ of 73/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does GlaxoSmithKline Pharmaceuticals' ROC (Joel Greenblatt) % compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, GlaxoSmithKline Pharmaceuticals ranks #16 out of 983 companies for ROC (Joel Greenblatt) %. This places GlaxoSmithKline Pharmaceuticals in the top 2% of its industry — outperforming the majority of peers. The industry median ROC (Joel Greenblatt) % is 11.46. GlaxoSmithKline Pharmaceuticals' value of 487.80% is 4156.5% above this benchmark. Historically, GlaxoSmithKline Pharmaceuticals' own ROC (Joel Greenblatt) % has ranged from 28.39 to 477.30 over the past decade. While the company's 10-year median is 153.41 vs. the industry median of 11.46, GlaxoSmithKline Pharmaceuticals has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROC (Joel Greenblatt) % for a Drug Manufacturers company?
The median ROC (Joel Greenblatt) % among Drug Manufacturers companies is 11.46, based on 983 companies in the industry. Companies in the top quartile (top 25%) have a ROC (Joel Greenblatt) % significantly above this median, while those in the bottom quartile fall well below. However, ROC (Joel Greenblatt) % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. GlaxoSmithKline Pharmaceuticals's current ROC (Joel Greenblatt) % of 487.80% is 4156.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROC (Joel Greenblatt) % mean?
A high ROC (Joel Greenblatt) % can signal that a stock is expensive relative to its fundamentals. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on GlaxoSmithKline Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median ROC (Joel Greenblatt) % is 11.46 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. GlaxoSmithKline Pharmaceuticals's current ROC (Joel Greenblatt) % is 487.80%, which is 218% above median its own 10-year median of 153.41. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is GlaxoSmithKline Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, GlaxoSmithKline Pharmaceuticals (NSE:GLAXO) is currently considered Fairly Valued. The stock's GF Value™ is ₹2,627.94, compared to a current price of ₹2,463.40 — trading 6.3% below its estimated fair value. The current ROC (Joel Greenblatt) % is 487.80%, which is 218% above median its 10-year median of 153.41 and 4156.5% above the Drug Manufacturers industry median of 11.46. GlaxoSmithKline Pharmaceuticals' overall GF Score™ is 73/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROC (Joel Greenblatt) % calculated?
ROC (Joel Greenblatt) % is calculated from a company's financial statements. For GlaxoSmithKline Pharmaceuticals (NSE:GLAXO), the current ROC (Joel Greenblatt) % is 487.80% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is GlaxoSmithKline Pharmaceuticals (NSE:GLAXO) Overvalued in 2026?
Based on GuruFocus' analysis, GlaxoSmithKline Pharmaceuticals stock appears to be undervalued.
The current stock price of ₹2,463.40 is trading 6.3% below its estimated GF Value™ of ₹2,627.94.
GuruFocus considers GlaxoSmithKline Pharmaceuticals to be Fairly Valued.
Key valuation signals for NSE:GLAXO:
ROC (Joel Greenblatt) %: 487.80% (218% above median its 10-year median of 153.41)
GF Value™: ₹2,627.94 vs. price of ₹2,463.40 (6.3% below fair value)
Industry Position: 4156.5% above the Drug Manufacturers median (#16 of 983)
No single metric tells the full story. See the NSE:GLAXO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
GlaxoSmithKline Pharmaceuticals Business Description
GlaxoSmithKline Pharmaceuticals Ltd is engaged interalia, in the business of manufacturing, distributing and trading in pharmaceuticals. It is healthcare organisation focused on uniting science, technology and talent to get ahead of disease. The company's product portfolio comprises a broad range of General Medicines which includes anti-infectives, pain management, vitamins, minerals, nutritionals, hormones, dermatologicals, vaccines for both children and adults, and specialty medicines for respiratory and oncology. Its focused brands are Augmentin, Ceftum, Flutivate, T-bat, Betnovate, Neosporin, Tenovate, Physiogel, Calpol and Calpol T. The company has single reportable segment. The company has presence in India, and also Outside India. It generates majority of revenue from India.
73GF Score
Get the complete analysis for NSE:GLAXO
ROC (Joel Greenblatt) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:GLAXO has been successfully added to your 
